Compare JRVR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRVR | AKBA |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 248.3M |
| IPO Year | 2014 | 2014 |
| Metric | JRVR | AKBA |
|---|---|---|
| Price | $3.52 | $0.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $4.72 | $3.92 |
| AVG Volume (30 Days) | 296.9K | ★ 5.6M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 125.82 | 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $687,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $0.81 |
| 52 Week High | $7.20 | $3.19 |
| Indicator | JRVR | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 43.47 |
| Support Level | N/A | $0.85 |
| Resistance Level | $4.26 | $0.98 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 22.13 | 23.69 |
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.